恩替卡韦治疗慢性HBV感染者KIR基因多态性与疗效的相关性研究

目的探讨慢性HBV感染者杀伤细胞免疫球蛋白样受体(killer immunoglobulin-like receptor,KIR)基因多态性及其与应用恩替卡韦疗效差异相关性。方法采用序列特异性引物聚合酶链反应(PCR-SSP)法,对60例应用恩替卡韦治疗的慢性HBV感染者(试验组)和60例健康对照者(对照组)的KIR基因进行基因分析,比较试验组和对照组的差异。60例患者中18例为治疗完全应答者(完全应答组),42例为非完全应答者(非完全应答组),比较2组之间差异。结果通过试验组和对照组的16种KIR基因分析,框架基因KIR2DL4、3DL2、3DL3和3DP1存在于所有个体中,其基因频率均为1.0。试验组KIR 2DS2和KIR2DS3基因型频率高于对照组(P值依次为0.038和0.035);完全应答组KIR2DS1、KIR3DS1和KIR2DL5基因型频率高于非完全应答组(P值依次为0.010、0.029和0.018)。结论 KIR2DS2、KIR2DS3可能是HBV的易感基因型,KIR2DS1、KIR3DS1、KIR2DL5可能与恩替卡韦抗HBV治疗有效应答有关。

Association between KIR genes polymorphisms and the efficacy of entecavir treatment in patients with chronic hepatitis B

ObjectiveTo explore whether KIR genotype polymorphisms is associated with HBV infection and the efficiency of chronic hepatitis B (CHB) patients treated with entecavir (ETV).MethodsPolymerase chain reaction with sequence -specific primers (PCR-SSP ) method was used to genotype KIR genes in 60 CHB patients and 60 healthy controls. Of the 60 patients, 18 were total responders to the treatment with ETV (complete response group, CRG) and 42 were null or partial responders (partial or null response group, PRG or NRG). The distributions of KIR genotypes were analyzed between the experimental group and the control group.ResultsAnalyzing 16 KIR genotypes between the experimental group and the control group, framework genes KIR2DL4, KIR3DL2, KIR3DL3 and KIR3DP1 were present in all individuals.The frequencies of them are both 1.0. The frequencies of KIR2DS2 and KIR2DS3 in the experimental group were significantly higher than those in the control group (P= 0.038 andP = 0.035, respectively). The frequencies of KIR2DS1 , KIR3DS1 and KIR2DL5 in CRG were significantly higher than those in PRG and NRG (P= 0.010 ,P = 0.029 andP = 0.018 respectively).ConclusionsKIR2DS2 and KIR2DS3 may be HBV susceptible genotypes. KIR2DS1, KIR3DS1 and KIR2DL5 may be of benefit to anti-HBV therapy with ETV.